Conmed: Q3 Earnings Snapshot

Conmed Corp. (CNMD) reported Q3 profit of $19.8M, or 66c/share, beating estimates. Revenue was $335.6M. Full-year EPS guidance is $4.54-$4.61, with revenue of $1.36B-$1.37B. According to Zacks, analysts expected $1.04 per share.

Original reporting
Published Oct 28, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Conmed: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$CNMDBullishHigh
01

Why it matters

The earnings beat and higher-than-expected full‑year guidance provide a fresh catalyst for the stock, likely prompting buying interest.

02

Market read

First‑report earnings and guidance for a U.S. med‑tech firm, offering a clear trading signal.

03

What to watch

Potential supply‑chain constraints or upcoming regulatory reviews could temper upside.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Conmed Corp. (CNMD) is a medical technology company based in Largo, Florida.

Company-level read

Ticker impact

$CNMDBullishHigh confidence
Context

Conmed Corp. reported Q3 earnings beating estimates and provided full-year guidance above expectations.

Expected impact

upward pressure as market prices in the earnings beat and higher guidance

Evidence & confidence

The beat and guidance are fresh, material information that traders can act on immediately.

Market effects

Medical technology sector may see modest uplift from a larger peer's earnings beat.

U.S. small‑cap healthcare stocks could benefit from the positive surprise.

Limited to investors focused on U.S. med‑tech equities.

Counterpoint

If guidance falls short of growth expectations, the stock could face disappointment despite the beat.

Key entities

  • Conmed Corp.

    Medical technology manufacturer reporting Q3 results.

Related articles

$CNMDMedAI 8/10

CNMD Q3 deep dive: stable revenue, margin improvement, and focus on core growth platforms

CONMED reported Q3 revenue of $335.6M, matching estimates, with adjusted EPS of $1.04, beating estimates by 3.7%. Adjusted EBITDA was $67.88M, a 2.9% beat. The company reconfirmed revenue guidance of $1.36B and raised adjusted EPS guidance to $4.58. Operating margin improved to 11.1%. International sales and AirSeal platform growth drove performance, while U.S. orthopedic sales declined.

$CNMDMed

Conmed Corp (CNMD) Q3 2026 Earnings Call Highlights: Solid Organic Growth Offset

Conmed Corp (CNMD) reported Q3 2026 earnings with global general surgery up 6.4% and orthopedics up 7.2%. U.S. general surgery grew 2%, while U.S. orthopedics declined slightly. CEO Pat Beyer highlighted strong performance in AirSeal and direct smoke evacuation, but noted variability in OEM business. CFO John Gallagher adjusted the organic growth range to 5.5% due to international performance. AirSeal grew in high single-digit to low double-digit range.

$CNMDHighAI 8/10

CONMED Q3 Earnings Call Highlights

CONMED reported Q3 organic revenue growth of 7.2% in orthopedic surgery, driven by international demand and BioBrace. Adjusted gross margin increased to 56.4%. The company updated its 2026 outlook, narrowing revenue growth to 5%-5.5% and raising adjusted EPS guidance to $4.54-$4.61. CONMED repurchased 1.2 million shares and expects to allocate $62 million to buybacks for the year.

$CNMDMed

CONMED (CNMD) Q3 2026 Earnings Call Transcript

CONMED (CNMD) reported Q3 2026 net revenue of $335.6M, with organic growth of 6.7% YoY. Adjusted EPS was $1.04, exceeding expectations. AirSeal and Buffalo Filter drove sales growth, with AirSeal showing strong performance in robotic and laparoscopic surgery. The company remains optimistic about long-term growth prospects for these products.

$CNMDMedAI 8/10

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) reported Q3 earnings of $1.04 per share, beating estimates by $0.04. Revenue was $335.56M, missing estimates by 0.37%. The company has beaten EPS estimates four times in the last four quarters. Shares are up 16.3% YTD. The Zacks Rank for the stock is #3 (Hold).